108 related articles for article (PubMed ID: 3729982)
1. Interaction between ellipticine derivatives and circular supercoiled DNA as revealed by gel electrophoresis. Possible relationship with the mechanisms of cytotoxicity .
Malvy C; Cros S
Biochem Pharmacol; 1986 Jul; 35(13):2264-7. PubMed ID: 3729982
[No Abstract] [Full Text] [Related]
2. A new series of ellipticine derivatives (1-(alkylamino)-9-methoxyellipticine). Synthesis, DNA binding, and biological properties.
Larue L; Rivalle C; Muzard G; Paoletti C; Bisagni E; Paoletti J
J Med Chem; 1988 Oct; 31(10):1951-6. PubMed ID: 3172128
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic effects of the lysosomotropic agents DNA-ellipticine, DNA-daunorubicin, and DNA-ellipticine:daunorubicin on L1210 leukemia cells.
Sorace RA; Sheid B
Cancer Treat Rep; 1979 Jan; 63(1):43-51. PubMed ID: 421232
[No Abstract] [Full Text] [Related]
4. Effects of the 6-alkyl substitution of ellipticine on the uptake by NIH-3T3 cells and on the cytotoxicity.
Deprés JP; Larue L; Paoletti J; Gouyette A
Anticancer Res; 1988; 8(1):191-6. PubMed ID: 3358635
[TBL] [Abstract][Full Text] [Related]
5. Interrelationship between affinity for DNA, cytotoxicity and induction of DNA-breaks in cultured L1210 cells for two series of tricyclic intercalators. Simplified analogues of ellipticine derivatives.
Pierson V; Pierre A; de Cointet P; Nguyen CH; Bisagni E; Gros P
Biochem Pharmacol; 1989 May; 38(9):1395-406. PubMed ID: 2719718
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships in a series of newly synthesized 1-amino-substituted ellipticine derivatives.
Ducrocq C; Wendling F; Tourbez-Perrin M; Rivalle C; Tambourin P; Pochon F; Bisagni E; Chermann JC
J Med Chem; 1980 Nov; 23(11):1212-6. PubMed ID: 7452670
[TBL] [Abstract][Full Text] [Related]
7. The biooxidation of cytotoxic ellipticine derivatives: a key to structure-activity relationship studies?
Meunier G; De Montauzon D; Bernadou J; Grassy G; Bonnafous M; Cros S; Meunier B
Mol Pharmacol; 1988 Jan; 33(1):93-102. PubMed ID: 3336351
[TBL] [Abstract][Full Text] [Related]
8. Ellipticine and derivatives induce breakage of L1210 cells DNA in vitro.
Paoletti C; Lesca C; Cros S; Malvy C; Auclair C
Biochem Pharmacol; 1979; 28(3):345-50. PubMed ID: 426849
[No Abstract] [Full Text] [Related]
9. Some antitumor derivatives of ellipticine deprived of mutagenic properties.
Lecointe P; Lesca P; Cros S; Paoletti C
Chem Biol Interact; 1978 Jan; 20(1):113-21. PubMed ID: 630641
[TBL] [Abstract][Full Text] [Related]
10. A CD study of interactions of ellipticine derivatives with DNA. Relations with the in vitro cytotoxicity.
Monnot M; Mauffret O; Simon V; Lescot E; Psaume B; Saucier JM; Belehradek J; Fermandjian S
FEBS Lett; 1990 Oct; 273(1-2):71-4. PubMed ID: 2226867
[TBL] [Abstract][Full Text] [Related]
11. Effects of ellipticine on cell survival and cell cycle progression in cultured mammalian cells.
Traganos F; Staiano-Coico L; Darzynkiewicz Z; Melamed MR
Cancer Res; 1980 Jul; 40(7):2390-9. PubMed ID: 6155993
[TBL] [Abstract][Full Text] [Related]
12. Ellipticine-induced protein-associated DNA breaks in isolated L1210 nuclei.
Filipski J; Kohn KW
Biochim Biophys Acta; 1982 Sep; 698(3):280-6. PubMed ID: 7138870
[TBL] [Abstract][Full Text] [Related]
13. Ellipticine, 9-hydroxyellipticine, and 9-hydroxyellipiticinum: some biochemical properties of possible pharmacologic significance.
Paoletti C; Auclair C; Lesca P; Tocanne JF; Malvy C; Pinto M
Cancer Treat Rep; 1981; 65 Suppl 3():107-18. PubMed ID: 7049365
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of cellular uptake of ellipticine by insulin preincubation.
Oster JB; Creasey WA
Eur J Cancer Clin Oncol; 1981 Oct; 17(10):1097-103. PubMed ID: 7040085
[No Abstract] [Full Text] [Related]
15. The in vitro involvement of topoisomerase II in the activity of aza-ellipticine analogues is not correlated with drug activity on isolated nuclei.
Vilarem MJ; Riou JF; Multon E; Gras MP; Larsen CJ
Biochem Pharmacol; 1986 Jul; 35(13):2087-95. PubMed ID: 3015146
[TBL] [Abstract][Full Text] [Related]
16. Repair of deoxyribonucleic acid lesions caused by adriamycin and ellipticine.
Ross WE; Smith MC
Biochem Pharmacol; 1982 May; 31(10):1931-5. PubMed ID: 7104026
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug--LDL complex via the LDL receptor pathway in vitro.
Samadi-Baboli M; Favre G; Bernadou J; Berg D; Soula G
Biochem Pharmacol; 1990 Jul; 40(2):203-12. PubMed ID: 2375762
[TBL] [Abstract][Full Text] [Related]
18. Dissolution and absorption of the antineoplastic agent ellipticine.
Rahman A; Cradock JC; Davignon JP
J Pharm Sci; 1978 May; 67(5):611-4. PubMed ID: 641792
[TBL] [Abstract][Full Text] [Related]
19. [Syntheses designed to produce 8-amino ellipticine. Synthesis and pharmacological properties of 8-nitro ellipticine].
Gansser C; Lévque X; Plat M; Viel C
Farmaco Sci; 1982 May; 37(5):283-97. PubMed ID: 7095141
[TBL] [Abstract][Full Text] [Related]
20. Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticinium.
Zwelling LA; Michaels S; Kerrigan D; Pommier Y; Kohn KW
Biochem Pharmacol; 1982 Oct; 31(20):3261-7. PubMed ID: 7150355
[No Abstract] [Full Text] [Related]
[Next] [New Search]
